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Abstract
The pathological accumulation of serous fluids in the pleural, peritoneal and pericardial space occurs in a variety of conditions. Since patient mana-
gement depends on right and timely diagnosis, biochemical analysis of extravascular body fluids is considered a valuable tool in the patient mana-
gement process.
The biochemical evaluation of serous fluids includes the determination of gross appearance, differentiation of transudative from exudative effusions 
and additional specific biochemical testing to assess the effusion etiology. This article summarized data from the most relevant literature concerning 
practice with special emphasis on usefulness of biochemical tests used for the investigation of pleural, peritoneal and pericardial effusions. Additio-
nally, preanalytical issues concerning serous fluid analysis were addressed and recommendations concerning acceptable analytical practice in serous 
fluid analysis were presented.
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Blood, urine and cerebrospinal fluid are standard 
samples analyzed in the clinical laboratory. How-
ever, occasionally the evaluation of serous ex-
travascular fluids (i.e. pleural, peritoneal and peri-
cardial) is requested. Biochemical analysis of such 
samples can provide the clinician valuable infor-
mation about the fluid’s etiology and refer him to 
final diagnosis and treatment options.
Pleural effusions
Pleural effusions result from excessive fluid forma-
tion and its accumulation in the pleural space. The 
most common conditions causing pleural effu-
sions are heart failure, malignancy, pneumonia, tu-
berculosis and pulmonary embolism. In patients 
presenting with pleural effusions, efforts should 
be made to find out the cause so that appropriate 
treatment can be instituted (1,2).
Patient history and physical examination are cru-
cial for the clinical evaluation of pleural effusions. 
They are followed by confirmation of pleural effu-
sion presence using radiological or/and ultrasound 
studies or computed tomography (CT) chest scans. 
Thoracentesis, the removal of pleural fluid using a 
needle or syringe, is performed either for diagnos-
tic or therapeutic purposes. It should be coupled 
with blood sampling (within 30 minutes from ob-
taining the pleural fluid sample) needed for fur-
ther effusion evaluation, i.e. the differentiation of 
transudative from exudative effusions (3).
In most cases of pleural effusions, especially if no 
underlying diagnosis is apparent, biochemical 
analyses provide important diagnostic informa-
tion. Various tests can be performed for pleural 
fluid (PF) analysis, either as sole or additional diag-
nostic tools to further determine the effusion’s eti-
ology (4,5).
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Appearance of pleural fluid
Although fluid appearance is a nonspecific tool in 
the evaluation of PF it can provide useful informa-
tion about the etiology of pleural effusion.
Most transudates and many exudates are clear, 
straw-colored, odorless and non-viscous fluids (6). 
A homogeneous bloody appearance, with PF he-
matocrit of 1-20% of peripheral, narrows the differ-
ential diagnosis to malignancy, embolism or trau-
ma. A PF hematocrit, exceeding half of the periph-
eral hematocrit, is indicative of hemothorax. Tur-
bidity of PF can be caused by either the presence 
of cells and debris or by a high lipid concentration 
in PF. A clear supernatant, after centrifugation of 
turbid PFs, indicates that turbidity is caused by 
cells and debris which might indicate the presence 
of empyema. Otherwise, if turbidity persists after 
centrifugation, it is probably due to high lipid con-
centration, suggesting the presence of chylotho-
rax or pseudochylothorax. Nevertheless, PF triglyc-
eride analysis is a more definitive test and concen-
trations > 1.2 mmol/L indicate that the PF is chyle. 
An anchovy-brown fluid may indicate amebic liver 
abscess while black fluid suggests Aspergillus in-
fection (4,5,7).
Differentiation of exudates from transudates
The initial step in the biochemical evaluation of 
pleural effusions is to determine whether they are 
transudative or exudative (Figure 1). Transudative 
pleural effusions are caused by systemic non-in-
flammatory conditions such as heart failure and 
cirrhosis. They respond to treatment of underlying 
disease. Exudative effusions are caused by an in-
flammatory or malignant process affecting the 
pleura, causing increased capillary permeability 
and fluid accumulation. Common causes of exu-
dates include pneumonia, cancer, tuberculosis and 
pulmonary embolism. An extensive diagnostic in-
vestigation is required to determine a definite di-
agnosis (1,5).
In clinical practice, Light’s criteria have been wide-
ly accepted to differentiate transudates from exu-
dates for the past 40 years (Table 1) (6,8). In their 
original study Light et al. reported a sensitivity of 
99% and specificity of 98% in identifying exudates. 
In subsequent studies, the original sensitivity of 
Light’s criteria was reproduced, but with lower 
specificities (ranging from 65% to 86%) and conse-
quently higher misclassification rates of transu-
dates into exudates (6,9,10). Despite this limitation, 
Light’s criteria were reported to be superior to clin-
ical judgment alone in the differentiation of tran-
sudates and exudates (11).
Various studies have focused on making Light’s 
criteria more cost-effective without affecting its di-
agnostic accuracy. Better diagnostic performances 
in comparison to Light’s criteria were obtained by 
quantifying exclusively PF protein and PF lactate 
dehydrogenase (LD) (12). An early investigation of 
PF cholesterol suggested that concentrations > 1.6 
mmol/L were a cost-effective single test that might 
be used as an alternative to Light’s criteria in the 
differentiation of exudative from transudative ef-
fusions (13). However, these results were not cor-
roborated by subsequent studies (14,15). Addition-
al biochemical parameters (and their combina-
tions) have been investigated to differentiate the 
two effusion types. Porcel et al. proposed meas-
urement of cholesterol and LD in PF as an alterna-
tive to Light’s criteria for the identification of exu-
dates without requiring blood sampling, while 
Costa et al. found that PF cholesterol > 1.2 mmol/L 
and/or PF LD > 200 U/L revealed similar diagnostic 
accuracy to Light’s criteria for the differentiation of 
PFs (16,17). Recently, concentration of ischemia-
modified albumin (IMA) has been found to be in-
creased in transudative pleural effusions compared 
to tuberculous effusions, and measurement of 
Table 1. Light’s criteria for the differentiation of pleural effu-
sions.
Pleural fluid PF/serum protein ratio
PF/serum 
LD ratio PF LD (U/L)
Transudative < 0.5 < 0.6 < 2/3 URL
Exudative* ≥ 0.5 ≥ 0.6 ≥ 2/3 URL
*Effusions are identified as exudative if one or more 
conditions are met.
LD – lactate dehydrogenase; PF – pleural fluid; URL – upper 
reference limit of serum LD.
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Figure 1. Biochemical analysis of pleural effusions.
LD – lactate dehydrogenase; URL – upper reference limit of serum LD; SEAG – serum effusion albumin gradient; NT-proBNP- N-ter-
minal brain natriuretic peptide precursor; CHF – congestive heart failure; IMA- ischemia-modified albumin; ADA – adenosine deami-
nase; IFN-γ - Interferon-γ; CRP – C-reactive protein.
STEP1 . APPEARANCE 
 - gross examination before centrifugation 
TRANSUDATE 
STEP 3 . SPECIFIC PLEURAL FLUID TESTS FOR EXUDATE EVALUATION: 
 
a) Total and differential cell count (total leukocytes > 500 x 106 / L, neutrophil 
predominance in acute inflammatory processes) 
b) pH (< 7.300 predicts shorter survival in malignant effusions) 
c) Glucose (< 3.4 mmol/L in parapneumonic effusions, malignant disease or 
tuberculosis) 
d) Triglycerides (> 1.2 mmol/L in chylothorax, < 0.6 mmol/L in pseudochylothorax) 
e) Cholesterol (< 5.2 mmol/L in chylothorax, > 5.1 mmol/L in pseudochylothorax) 
f) ADA (> 40 U/L in tuberculous peritonitis)  
g) IFN-γ (lack of definite cutoff point) 
h) Amylase (pleural fluid/serum ratio > 1 in pancreatic pseudocyst, malignant disease, 
liver cirrhosis, esophageal rupture) 
i) Creatinine (pleural fluid/serum ratio > 1 in urinothorax) 
j) CRP (> 53 mg/L in parapneumonic versus malignant effusions). 
PLEURAL FLUID  
STEP 2 . TRANSUDATE/EXUDATE DIFFERENTIATION 
 
Light’s criteria for pleural fluid exudate: 
a) Pleural fluid/serum protein ratio ≥ 0.5 and/or 
b) Pleural fluid/serum LD ≥ 0.6 and/or 
c) Pleural fluid LD ≥ 2/3 URL. 
 
Useful additional tests for exudate identification:  
a) SEAG (in patients treated with diuretics) < 12 /L 
b) Pleural fluid cholesterol > 1.2 mmol/L 
c) Pleural fluid NT- proBNP (in patients with CHF) < 
1500 ng/L 
d) Pleural fluid IMA < 4711 ng/mL. 
THORACENTESIS 
EXUDATE 
Treatment of underlying disease 
pleural IMA showed good diagnostic performanc-
es (although not superior to Light’s criteria) in tran-
sudate/exudate differentiation (18). Additional bio-
chemical parameters have also been investigated 
for this purpose, including alkaline phosphatase 
(ALP), creatine kinase and uric acid. They showed 
poorer diagnostic performances compared to 
Light’s criteria (19).
It has been estimated that up to 25% of cardiac-
related pleural effusions are misclassified as exu-
dative in patients with congestive heart failure 
(CHF) due to the use of diuretics (20). Diuretic ther-
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apy in patients with CHF was reported to cause 
fluid shifting from the pleural space, thus elevat-
ing concentrations of various PF components, in-
cluding PF protein and PF LD. Consequently, tran-
sudative pleural effusions associated with CHF 
could fulfill exudative diagnostic criteria (4,21). Af-
ter the introduction of the serum effusion albumin 
gradient (SEAG), calculated as the difference be-
tween serum and PF albumin concentration, the 
misclassification of transudative effusions in pa-
tients treated with diuretics was significantly re-
duced. If SEAG is > 12 g/L, the effusion is classified 
as transudate. However, because of its low sensi-
tivity, the albumin gradient should not be used in-
dividually to distinguish transudates from exu-
dates. Thus, if the clinical appearance suggests 
transudative effusion, particularly in cases of CHF 
or cirrhosis, but the PF is exudative according to 
Light’s criteria, SEAG calculation is recommended 
(9,10,14). In recent years it has been shown that N-
terminal brain natriuretic peptide precursor (NT-
proBNP) concentrations are increased in PF and se-
rum of patients with CHF and pleural effusion. 
Pleural fluid NT-proBNP values ≥ 1500 ng/L can dif-
ferentiate pleural effusions caused by heart failure 
from pleural effusions caused by other etiology 
with sensitivity and specificity of 91% and 93%, re-
spectively (20). Additional studies demonstrated 
the superiority of pleural NT-proBNP determina-
tion over Light’s criteria for the identification of 
cardiac-related pleural effusions. However, caution 
is needed when interpreting NT-proBNP results, as 
concentration of NT-proBNP is physiologically 
raised in the elderly and in patients with renal fail-
ure (22-25).
When comparing the discriminative properties of 
different biochemical markers for the identifica-
tion of exudative effusions, the meta-analysis pub-
lished by Heffner et al. should be considered. The 
authors confirmed that combinations of two or 
three tests performed only in PF specimens (i.e. 
the combined use of PF LD and PF cholesterol or 
PF LD, PF cholesterol and PF protein), showed simi-
lar diagnostic performances to modified Light’s 
criteria, reducing the costs of diagnosis and avoid-
ing the need for blood sampling. Heffner et al. also 
demonstrated that excluding PF LD from Light’s 
criteria did not alter the diagnostic accuracy of the 
remaining combination (i.e. PF/serum LD ratio and 
PF/serum protein ratio). However, no superior com-
bination of tests was proposed (26).
All of the aforementioned tests dichotomize effu-
sions into transudative or exudative by comparing 
the results to a cut-off point. The diagnostic per-
formances of each of these tests are described by 
means of sensitivity and specificity. Applicability 
of sensitivity and specificity values on individual 
patients in clinical practice is limited, because 
these measures do not describe the probability of 
disease if a positive test result is obtained. In addi-
tion, the combination of multiple tests, using a sin-
gle cut-off point for each test, increases sensitivity 
but decreases specificity, implying the need for 
additional (and often unnecessary) tests to clarify 
diagnosis. A Bayesian approach addresses the limi-
tations of binary testing by quantifying diagnostic 
confidence. This concept suggests that a test alone 
does not differentiate exudate from transudate, 
rather that the test only influences the pre-test 
probability of being a transudate or exudate. Mul-
tilevel likelihood ratios, for tests routinely per-
formed to discriminate between transudates and 
exudates, were reported and can be used to esti-
mate the post-test probability of exudative effu-
sions. However, the familiarity and simplicity of 
Light’s criteria should be balanced against the in-
troduction of new and cumbersome methods for 
differentiating transudates from exudates (27-29).
Evaluation of exudative effusions
Once a pleural effusion is characterized as an exu-
date, the next challenge is to identify its etiology. 
Depending on clinical presentation, exudative ef-
fusions need additional testing (Figure 1). This in-
cludes total and differential cell counts, smears 
and cultures to identify infection, additional bio-
chemical testing, cytological analysis and testing 
for markers of tuberculous pleuritis (5,8).
In general, most exudates have > 500 x 106 / L leu-
kocytes (30). Although differential leukocyte count 
in PF is of limited diagnostic value, it reflects the 
stage of the inflammatory response and narrows 
the diagnostic possibilities. Neutrophil predomi-
http://dx.doi.org/10.11613/BM.2014.014 Biochemia Medica 2014;24(1):123–37 
  127
Milevoj Kopcinovic L, Culej J. Pleural, peritoneal and pericardial effusions
nance indicates an acute inflammatory process af-
fecting the pleura that may occur in the case of 
parapneumonia, pulmonary embolism, viral infec-
tions, gastrointestinal diseases and tuberculous 
pleuritis. Predominance of mononuclear cells indi-
cates a subacute or chronic process. Pleural lym-
phocytosis is indicative of malignant or tubercu-
lous pleuritis, whereas pleural eosinophilia (at least 
10% of eosinophils) is caused mainly by blood or 
air in the pleural space (i.e. malignancy or pneu-
mothorax) (4,6,8).
The exudative pH ranges from 7.440 to 7.300 (30). 
Several conditions, such as systemic acidosis, local 
anesthetics entered in the pleural space or Proteus 
infections, can cause local alkalosis and modify the 
pH values of the PF. Therefore, PF pH results should 
always be interpreted in accordance to the clinical 
context. A pH value below 7.200 (and/or PF LD 
higher > 3 times the upper serum reference limit) 
in patients with parapneumonic effusion indicates 
the need for fluid drainage (31). A pH value below 
7.300 in patients with malignant effusions predicts 
shorter survival and a poorer response to chemical 
pleurodesis. When PF pH is not available, low PF 
glucose concentration (< 3.4 mmol/L) indicates the 
presence of complicated parapneumonic effusion, 
malignant disease or tuberculosis (1,6,8).
Determination of triglyceride and cholesterol con-
centrations is useful in the diagnosis of chylotho-
rax and pseudochylothorax. A chylothorax is de-
fined as the accumulation of lymph or chyle in the 
pleural space after leak from the thoracic duct, 
most often due to trauma, surgery or malignancy. 
A pseudochylothorax results from the accumula-
tion of cholesterol and/or lecithin and globulin rich 
fluid in long standing PFs. PF triglyceride concen-
trations > 1.2 mmol/L are confirmatory of chylot-
horax. Usually, PF cholesterol is determined simul-
taneously to exclude the presence of pseudochy-
lothorax: concentrations < 5.2 mmol/L are associ-
ated with chylothorax. PF triglycerides < 0.6 
mmol/L and PF cholesterol > 5.1 mmol/L are found 
in pseudochylothorax. Nevertheless, the gold 
standard for diagnosing chylothorax is the detec-
tion of chylomicrons in PF by means of lipoprotein 
analysis (22,32).
In clinical practice, the diagnosis of tuberculous 
pleurisy is usually established using the combina-
tion of PF microscopic examination and PF cul-
tures. The sensitivity of these conventional meth-
ods for diagnosing tuberculous pleural effusions 
was reported to be less than 50%. Thus, several bi-
ochemical markers have been proposed to facili-
tate the diagnosis of tuberculous pleurisy. 
Interferon-γ (IFN-γ) and adenosine deaminase 
(ADA) are both released during the immune re-
sponse to mycobacterial antigens in the pleura 
and have been extensively studied (33). IFN-γ has 
proven to be a sensitive and specific marker in di-
agnosing tuberculous pleural effusions. Investiga-
tors reported sensitivity and specificity of 89% and 
97%, respectively (34,35). ADA is an enzyme in-
volved in purine catabolism and is thought to re-
flect the activity of immune cells (6,34). It is re-
leased by activated lymphocytes, macrophages 
and neutrophils, and is considered a nonspecific 
marker of inflammation (36). Elevated ADA activity 
in PF is a sensitive and specific marker for the diag-
nosis of tuberculous pleuritis, particularly in high 
prevalence areas, with reported sensitivity of 92% 
and specificity of 90% at a generally accepted cut-
off point of 40 U/L (37,38). Despite the high diag-
nostic performances of both biomarkers, ADA is 
commonly used in clinical practice, due to lower 
costs and the lack of a definite cutoff point for 
IFN-γ. However, since none of these PF biomarkers 
is specific for tuberculous pleuritis, results should 
be interpreted in accordance with clinical and 
microbiologic findings (22,33,37,38).
Additional biomarkers have been studied in the 
setting of tuberculous pleural effusions, including 
PF neopterin, leptin, lysozyme, interleukine (IL)-6, 
IL-1β, IL-8 and others. Variable diagnostic perform-
ances obtained and high costs preclude their in-
troduction into routine clinical practice. To over-
come the limitations of individual tests, various 
scoring systems, using clinical and laboratory data, 
have been proposed for the differentiation of tu-
berculous and malignant pleural effusions. They 
seem to perform better than any single test (36).
Cytological examination of suspected malignant 
PFs, although fast and efficient in cancer diagno-
sis, can result in false negative results in up to 40% 
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of patients. The diagnostic performances of cytol-
ogy are related to tumor type, tumor burden in 
the pleural space and the cytologist’s competence 
(1). Although single PF tumor markers such as car-
cinoembryonic antigen (CEA), CA 125, CA 15-3 and 
CYFRA 21-1 have been investigated as noninvasive 
procedures for diagnosing pleural malignancy, the 
obtained results are discordant and the usefulness 
limited due to low sensitivity. In an effort to im-
prove sensitivity, combinations of tumor markers 
have been studied, such as CEA, CA 125 and CY-
FRA 21-1 or CEA, CA 15-3, CYFRA 21-1 and CA 125. 
It was demonstrated that such combinations could 
be considered valuable complementary tools in 
the diagnosis of malignant PF, improving the diag-
nostic value of PF cytology. However, the routine 
determination of tumor markers in the diagnosis 
of malignant pleural effusions is not recommend-
ed because it is not cost-effective. In cases of sus-
picious malignant pleural effusion and negative 
cytological findings, or in the absence of an obvi-
ous primary source, the determination of tumor 
markers may be helpful as an alternative diagnos-
tic tool indicating the need for pleural biopsy 
(6,10,39,40).
High activity of amylase (AMY) in PF is defined as 
values exceeding the serum reference range or as 
PF to serum AMY ratio > 1 (22). Elevated PF AMY is 
found in patients with pancreatic disease and pan-
creatic pseudocysts, malignant disease, liver cir-
rhosis and esophageal rupture. The routine meas-
urement of AMY in PFs is not useful in the absence 
of these indications (41,42). Increased PF creatinine 
concentrations (PF/serum creatinine ratio > 1) are 
useful in the diagnosis of urinothorax. The PF has 
typically transudative characteristics with marked 
urine odor, low glucose concentrations and low 
pH (10,43). Although rare, cerebrospinal fluid (CSF) 
can accumulate in the pleural space and result in 
an effusion. The presence of CSF is suggested by 
very low protein concentration in the PF and con-
firmed by β2-transferrin detection, which is nor-
mally present only in CSF (43). PF immunological 
tests, such as determination of antinuclear anti-
body (ANA) titer or rheumatoid factor (RF) levels 
are accessible but add little diagnostic information 
to serum immunological analyses (4,5,22).
Features of PF analysis that discriminate infection 
from inflammation in the complicated versus non-
complicated setting include pleural C-reactive pro-
tein, IL-8, IL-6, tumor necrosis factor (TNF)-α and 
procalcitonin. Pleural CRP is higher in non-malig-
nant versus malignant exudates, with high sensitiv-
ity and specificity for parapneumonic effusion. 
Further studies showed that a PF CRP cut-off value 
of 53 mg/L has 100% sensitivity in identifying par-
apneumonic versus tuberculous or malignant effu-
sions (44). CRP measured together with IL-8 may 
differentiate complicated from uncomplicated 
parapneumonic effusions with high sensitivity and 
specificity (4).
Peritoneal effusions
Peritoneal effusions (or ascites) represent the path-
ological collection of fluid in the peritoneal cavity. 
Common causes include liver cirrhosis, malignan-
cy, congestive heart failure, tuberculosis, nephrotic 
syndrome, pancreatic disease and dialysis (6). His-
tory and physical examination provide clues to the 
possible etiology of ascites formation. Abdominal 
radiological, ultrasound and CT studies can help 
detect small volumes of peritoneal fluid as well as 
assess the possible etiology of ascites. However, 
diagnostic paracentesis, i.e. the removal of perito-
neal fluid, is recommended in patients presenting 
with new-onset ascites, requiring hospitalization 
due to the presence of ascites or in cases of unex-
plained deterioration of clinical findings (45,46). 
Abdominal paracentesis with appropriate ascitic 
fluid biochemical analysis is considered the most 
rapid and cost-effective method for diagnosing 
the cause of ascites (47).
Appearance of peritoneal fluid
Ascites is a clear, straw-colored fluid and usually 
reflects the presence of cirrhosis. Bloody ascitic 
fluid, if not caused by traumatic tap, indicates ma-
lignancy, pancreatitis or abdominal trauma. When 
the bloody appearance of ascitic fluid is caused by 
traumatic tap, the fluid tends to clear up and/or 
tends to clot when left to stand after paracentesis. 
Purulent ascites is usually caused by abdominal in-
fection and accompanied by an increased number 
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of polymorphonuclear (PMN) leukocytes. In condi-
tions of complicated hemorrhagic pancreatitis, the 
ascitic fluid color ranges from tea-colored to black. 
Bile stained ascites is usually found in gallbladder 
or intestine perforation, cholecystitis or acute pan-
creatitis. Milky or turbid ascites appearance is char-
acteristic for lymph effusions due to high triglycer-
ide content. The turbidity of chylous ascites can be 
cleared by addition of a few drops of ether. Pseu-
dochylous ascites also appears turbid but is not 
cleared by ether. Black colored ascites can be 
found in malignant melanoma (6,48).
Differentiation of exudates from transudates
As with pleural effusion analysis, the biochemical 
evaluation of ascites begins with differentiation of 
transudative from exudative effusions (Figure 2). 
This concept is based on the assumption that as-
cites, formed by exudation from the peritoneal 
surface affected by inflammatory process or tu-
mor, has high protein concentrations. Conversely, 
fluid formed by transudation as a result of system-
ic conditions such as cirrhosis, heart failure or ne-
phrotic syndrome, has low protein concentrations 
(49). Ascites protein cut-off in the range of 25 to 30 
g/L has been traditionally used for separating as-
cites into transudative or exudative. However, this 
approach yielded poor sensitivity and frequent 
misclassifications. Furthermore, it does not address 
ascites of mixed origin, i.e. caused by an underly-
ing disorder besides portal hypertension. Addi-
tionally, it was observed that healthy women fre-
quently have a peritoneal fluid protein concentra-
tion above 40 g/L, well into the exudative range. A 
modification of the original Light’s criteria for the 
identification of exudative ascites was suggested 
(Table 2) (6,45). Other biochemical parameters, 
such as ascitic/serum bilirubin ratio, ascitic choles-
terol and ascitic/serum cholesterol ratio, have been 
investigated for the differentiation of transudative 
from exudative ascites, but have not been imple-
mented into routine practice due to lack of repro-
ducibility between studies. Furthermore, a practi-
cal model, including determinations of total pro-
tein, LD, TNF-α, complement C4 and haptoglobin 
in ascitic fluid, was investigated, that correctly clas-
sified 70% of unknown cases of malignant ascites 
(6,50,51). Although promising, these results need 
to be further developed in the clinical setting be-
fore implementation into routine clinical practice 
(51). Serum ascites albumin gradient (SAAG) has 
been proposed as a physiologically based alterna-
tive to the traditional classification of ascites into 
transudates/exudates (52). SAAG is calculated as 
the difference between serum and ascites albumin 
concentration and was demonstrated to correlate 
directly with measured portal pressure (6). Conse-
quently, SAAG ≥ 11 g/L suggests the presence of 
portal hypertension, while SAAG values < 11 g/L 
are found in patients with normal portal pressure. 
In a large prospective study, SAAG and ascitic total 
protein concentration yielded a diagnostic accura-
cy of 97% and 56%, respectively, in the differentia-
tion of ascites caused by portal hypertension (49). 
This marked difference in accuracies was explained 
by factors influencing these parameters: while 
SAAG directly correlates only with portal pressure, 
ascitic total protein concentrations are indirectly 
related to portal pressure but directly related to 
serum protein concentrations. In patients with cir-
rhosis, these influencing factors contribute varia-
bly, explaining the highly variable ascitic total pro-
tein concentration. Given the superiority of the 
SAAG concept, the replacement of the traditional 
transudate/exudate concept was proposed. Ascitic 
fluid should be classified as high-albumin gradient 
or low-albumin gradient depending on the SAAG 
value (49,53,54). Both SAAG and ascitic fluid pro-
tein concentration are recommended for the initial 
evaluation of ascitic fluid in cirrhosis, proposed by 
the American Association for the Study of Liver 
Disease (AASLD) and British Society of Gastroen-
terology (47,55).





Transudative < 0.5 < 0.6 < 400
Exudative* ≥ 0.5 ≥ 0.6 ≥ 400
*Effusions are identified as exudative if at least two 
conditions are met.
LD – lactate dehydrogenase.
Table 2. Modification of Light’s criteria for the differentiation 
of ascites.
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Figure 2. Biochemical analysis of peritoneal effusions.
LD – lactate dehydrogenase; SAAG – serum ascites albumin gradient; SBP – spontaneous bacterial peritonitis; ADA - adenosine dea-
minase. 
TRANSUDATE EXUDATE 
STEP 3 . SPECIFIC PERITONEAL FLUID TESTS FOR EXUDATE 
EVALUATION: 
 
a) Total and differential cell count (PMN leukocyte count ≥ 500 
x 106 / L in SBP) 
b) Glucose (lower than in serum in tuberculous peritonitis, 
carcinomatosis and SBP) 
c) Amylase (≥ 2000 U/L in pancreatic ascites, gut perforation, 
ruptured pseudocyst) 
d) Urea and creatinine (elevated above respective serum 
reference ranges in urinary bladder rupture) 
e) Triglycerides (> 2.25 mmol/l or higher than in 
corresponding serum in chylous ascites) 




STEP1 . APPEARANCE 
 - gross examination before centrifugation 
STEP 2a . TRANSUDATE/EXUDATE DIFFERENTIATION 
 
Modified Light’s criteria for peritoneal fluid exudate: 
a) Peritoneal fluid/serum protein ratio ≥ 0.5 
b) Peritoneal fluid/serum LD ≥ 0.6 
c) Peritoneal fluid LD ≥ 400 U/L. * 
* Effusions are identified as exudates if at least two 
criteria are met. 




a) ≥  11 g/L - high albumin gradient peritoneal 
effusion; transudate  
b) <  11 g/L -  low albumin gradient peritoneal 
effusion; exudate  
or 
Treatment of underlying disease 
It is important to note some methodological issues 
regarding albumin determination. In patients with 
cirrhosis, serum albumin concentrations below 11 
g/L can be expected. In this case, depending on 
method assay range, incorrect results of SAAG cal-
culation due to assay inaccuracy in the low range 
could occur, or the SAAG cannot be calculated at 
all. Chylous ascites can have falsely elevated albu-
min concentrations due to lipid fraction interfer-
ence. Furthermore, since globulins contribute to 
the colloid osmotic pressure, but are inversely cor-
related to the SAAG, the presence of hyperglob-
ulinemia (> 50 g/L) can have a pronounced impact 
on SAAG, falsely decreasing its values (6,45,56). It is 
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still unclear if the time interval between serum and 
ascites sampling is of importance for SAAG calcu-
lation (57).
Specific analyses for ascites evaluation
After differentiation of ascites into two broad cat-
egories, specific biochemical analyses can be use-
ful for further evaluation of ascites etiology (Figure 
2).
All ascitic fluid samples should be screened for the 
development of spontaneous bacterial peritonitis 
(SBP). PMN leukocyte count in ascitic fluid ≥ 250 x 
106 / L is the gold standard criterion for SBP diag-
nosis. Although not specific, it is a highly sensitive 
indicator of SBP. Ascitic PMN count of ≥ 500 x 106 / 
L is considered specific for the diagnosis of SBP 
(47,55,58,59). Because of poor prognosis, antibiotic 
treatment must be instituted immediately in all 
patients with suspected SBP, without waiting for 
microbiology test results (59). In order to reduce 
time for diagnosis, the usefulness of leukocyte es-
terase strip testing for diagnosing SBP in cirrhotic 
patients with ascites was investigated. Very high 
sensitivity and specificity of urine strip tests were 
reported compared against the gold standard. Ad-
ditionally, it was suggested that the rapidity, low 
cost and wide availability of urine test strips could 
improve the management of patients with SBP, es-
pecially in cases of inflammatory cell clumping in 
ascitic fluid specimens (60-62). The determination 
of glucose in ascitic fluid is of little relevance in elu-
cidating the etiology of ascites. Glucose concen-
trations found in ascitic fluid reflect those found in 
serum. However, low glucose has been reported in 
tuberculous peritonitis, carcinomatosis and SBP 
due to leukocyte or bacterial consumption. De-
creased ascites protein concentrations are associ-
Figure 3. Biochemical analysis of pericardial effusions.
LD – lactate dehydrogenase; SEAG – serum effusion albumin gradient; ADA - adenosine deaminase. 
TRANSUDATE 
EXUDATE 
STEP 3 . SPECIFIC PERICARDIAL FLUID TESTS: 
- ADA (> 40 U/L in tuberculous pericarditis) 
PERICARDIAL FLUID 
STEP 2 . TRANSUDATE/EXUDATE DIFFERENTIATION 
 
Light’s criteria for pericardial fluid exudate: 
a) Pericardial fluid/serum protein ratio ≥ 0.5 and/or 
b) Pericardial fluid/serum LD ≥ 0.6 and/or 
c) Pericardial fluid LD ≥ 200 U/L. 
 
Useful additional tests for exudate identification:  
a) SEAG (in patients treated with diuretics) < 12 /L 
b) Pericardial fluid/serum cholesterol ratio > 0.3 
PERICARDIOCENTESIS 
STEP1 . APPEARANCE 
 - gross examination before centrifugation 
Treatment of underlying disease 
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ated with high risk for developing SBP. AMY activi-
ty in ascitic fluid ≥ 2000 U/L is useful in identifying 
pancreatic ascites. Elevated ascitic AMY activity is 
also found in gut perforation with leakage into the 
peritoneum, ruptured pseudocysts and mesenter-
ic thrombosis (6,45). The diagnostic utility of sev-
eral tumor markers has been evaluated in diagnos-
ing malignant ascites, especially in situations of in-
conclusive cytological findings. In general, they 
are considered of little clinical value compared to 
corresponding analyses in serum (63). Determina-
tions of urea and creatinine concentrations in as-
citic fluid can be useful to differentiate ascites from 
urine (45). Elevated concentrations of ascitic fluid 
urea and creatinine compared to simultaneously 
drawn serum, associated with elevated serum urea 
but normal serum creatinine, are indicative of the 
presence of urine (64). Chylous ascites is a rare but 
serious complication of abdominal surgery, ab-
dominal malignancies, inflammatory diseases, ab-
dominal infections or trauma. Chylous ascites can 
be differentiated from pseudochylous effusions by 
its high triglyceride concentration (higher than 
2.25 mmol/L or higher than in corresponding se-
rum) (45,65,66). However, since lymphatic fluid 
triglyceride concentration is associated with the 
patient’s nutritional status, the determination of 
triglyceride levels in serum and ascites simultane-
ously is necessary. Alternatively, ascites triglyceride 
concentration higher than 1.2 mmol/L are consid-
ered suggestive of chylous ascites (65). A system-
atic review, investigating the usefulness of ADA in 
ascitic fluid as a diagnostic tool in peritoneal tu-
berculosis, included 254 patients and revealed an 
optimal ADA cut off point at ≥ 39 U/L. An excellent 
diagnostic efficiency for the diagnosis of perito-
neal tuberculosis was found with a sensitivity of 
100% and specificity of 97% (67). In specific situa-
tions, the determination of other parameters in as-
citic fluid may be clinically relevant: total bilirubin 
in cases of biliary leak, ALP in cases of intestinal 
obstruction or perforation, ammonia in cases of 
ruptured appendix, lactic acid in bacterial perito-
nitis, GGT in patients with alcoholic cirrhosis (6).
Pericardial effusions
Pericardial effusions are characterized by accumu-
lation of fluid in the pericardial space due to injury 
of the pericardium or pericarditis (6). Transudative 
pericardial effusions are usually associated with 
heart failure, hypoalbuminemia, post-radiation 
therapy and renal insufficiency, while exudative ef-
fusions result secondary to pericardial inflamma-
tory, infectious, malignant or auto-immune proc-
esses (6,68). Echocardiography is used to diagnose 
the presence of pericardial effusions, but cannot 
be used to clearly determine their etiology. Peri-
cardiocentesis, the removal of pericardial fluid, is 
used both for diagnostic and therapeutic purpos-
es (6).
Appearance of pericardial fluid
Pericardial fluid is clear and pale yellow. Turbid flu-
id is indicative of infection or malignancy. Bloody 
fluid suggests malignant or tuberculous etiology. 
A milky appearance results from the presence of 
chylopericardium (6).
Differentiation of exudative from transudative 
pericardial effusions
Contrary to the well-established biochemical eval-
uation of pleural effusions, data concerning the di-
agnostic usefulness of biochemical tests for the 
evaluation of pericardial fluid are scarce. Meyers et 
al. evaluated the ability of various biochemical 
tests to correctly classify effusions as transudates 
or exudates in a retrospective study. The authors 
showed that exudative and transudative pericar-
dial effusions can be differentiated using fluid total 
protein concentrations > 30 g/L, fluid/serum total 
protein ratio > 0.5 and fluid LD > 300 U/L. The 
highest diagnostic accuracy in identifying exu-
dates was obtained using fluid/serum LD ratio > 
0.6 (87%) (69). It must be emphasized that these re-
sults must be interpreted with caution because 
retrospective studies can potentially result in bi-
ased results and inaccurate conclusions. In a pro-
spective study, Light’s criteria were applied to peri-
cardial effusion differentiation and yielded a diag-
nostic efficiency of 94%, with a sensitivity and spe-
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cificity in identifying exudates of 98% and 72%, 
respectively. Similarly to pleural effusion differen-
tiation, the misclassification of transudative into 
exudative pericardial fluid was reported when 
Light’s criteria were applied to patients receiving 
diuretic therapy. The application of the SEAG con-
cept, used in the evaluation of pleural effusions, 
yielded a sensitivity of 90% and specificity of 89% 
for the identification of pericardial exudates and 
was superior to Light’s criteria in patients on diu-
retics. Pericardial effusion cholesterol concentra-
tions ≥ 1.2 mmol/L yielded a diagnostic efficiency 
of 83% in identifying pericardial exudates, with a 
sensitivity of 88% and specificity of 56%. When flu-
id/serum cholesterol ratio was calculated, im-
proved diagnostic performances were obtained: a 
cut-off set at 0.3 yielded a diagnostic efficiency of 
88%, sensitivity of 91% and specificity of 83% 
(6,70). However, Ben-Horin et al. investigated the 
composition of physiological pericardial fluid in a 
small cohort of patients selected for elective open-
heart surgery. They found that pericardial fluid 
concentrations of small molecules (i.e. urea, uric 
acid, glucose and creatinine) were similar to those 
found in serum. In contrast, pericardial fluid LD 
concentration was 2.5-fold higher than serum LD, 
and total protein concentrations were 0.6 of their 
serum levels (71). The discriminatory accuracy of 
pericardial fluid/serum LD ratio, pericardial fluid 
LD and the pericardial fluid/serum total protein ra-
tio was found to be unsatisfactory (72). Consider-
ing these findings, caution is needed when inter-
preting pericardial fluid LD and total protein ac-
cording to Light’s criteria, because pericardial tran-
sudates may have levels of these parameters in the 
exudative range (70-73).
Evaluation of exudative pericardial effusions
The measurement of ADA in pericardial effusions 
has proven to be a rapid and accurate tool in iden-
tifying tuberculous pericarditis, especially in high 
prevalence areas. At a cut-off value set at 40 U/L, 
the diagnostic usefulness of ADA measurement in 
tuberculous pericarditis diagnosis yields 88% sen-
sitivity and 83% specificity (74). CEA and neuron 
specific enolase have been investigated to identify 
malignant pericardial effusions. Although promis-
ing, the diagnostic utility of tumor markers is limit-
ed by the small number of patients investigated (6).
Preanalytical and analytical 
considerations
Since recommendations addressing the preanalyt-
ical phase for serous fluid testing are unavailable, 
serous fluid collection, handling and processing 
should be performed following the guidelines for 
serum or plasma specimens (64). After collection, 
serous fluid samples should be transferred into ap-
propriate containers (Table 3) and immediately 
transported to the laboratory (75,76). Serum sam-
ples for the calculation of ratios and gradients 
should be collected within 30 minutes from serous 
fluid sampling (3).
In recognition of the difficulties faced by clinical 
laboratories in serous fluid analysis the Clinical and 
Laboratory Standards Institute (CLSI) developed 
Analysis Container Recommendation
pH analysis heparinized syringe sampling done in anaerobic conditions; analyze promptly using a blood gas analyzer
Cell count, 





allow complete clotting of samples collected in non-additive 
containers/tubes at room temperature; bloody and turbid serous 
fluids may be unsuitable for analysis
Glucose, lactate tubes with glycolitic inhibitors lactate: specimen chilling during transportation to the laboratory
EDTA - ethylenediaminetetraacetic acid.
Table 3. Containers used for serous fluid biochemical analysis.
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the document C49-A: Analysis of body fluids in 
clinical chemistry. A brief summary of the accepta-
ble practice without the need for extensive meth-
od verification procedures is given in Table 4 
(10,64,75).
Conclusions
When analyzing serous fluids, an approach ad-
dressing directly a specific clinical question, guid-
ed by the collaboration of specialists in laboratory 
medicine and clinicians, seems to be more appro-
priate and ultimately cost-effective than ordering 
a set of all available tests. Accordingly, diagnostic 
algorithms should be adopted to establish the bi-
ochemical analysis of serous fluids as an efficient 
tool helping the management of patients with se-
rous effusions.
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Recommendation
The lack of manufacturers’ claims for alternate samples obligates clinical laboratories to verify the performance of commercial •	
assays for their possible use in serous fluid analysis. 
The preconditions for using a commercial assay for analysis in an alternate body fluid include that the measurement system in •	
the routine specimen type has acceptable test characteristics, has calibrators and controls, is traceable to a reference method 
and has available external proficiency testing.
Matrix effects, resulting from variations in serous fluid constituents’ concentrations, can alter fluid surface tension, viscosity •	
and miscibility in a reaction mixture and potentially influence the measurements in assays intended for use in standard fluid 
analysis (inaccurate pipetting, inadequate mixing). This matrix effects can potentially cause erroneous results and should be 
given full consideration when analyzing serous fluids. 
Lack of reference ranges for serous fluid analysis should be compensated for by interpreting the results in conjunction with •	
simultaneously collected serum specimens.
The test report should include the measured value, type of fluid tested and a statement that accuracy might be affected by •	
sample type, and that the obtained results should be interpreted in the clinical context. 
Table 4. Recommendations for acceptable practice in serous fluids analysis (10,64,75).
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